Harneys advises QingSong Health Corporation on its Hong Kong IPO

23 Dec 2025

Harneys acted as Cayman Islands counsel to QingSong Health Corporation (QingSong Health) on its initial public offering (IPO) and listing on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) under stock code 2661. The company’s shares commenced trading on HKEX on 23 December 2025, with the share price rising by approximately 1.5 times on its debut day, underscoring strong market reception.

QingSong Health offered an aggregate of 26,540,000 shares under the global offering at an offer price of HKD 22.68 per share, with a 15 per cent over-allotment option. QingSong Health is a leading digital healthcare service provider in China, operating integrated healthcare and health insurance-related services supported by its proprietary AI technology stack, Aicare. Its platform connects insurer partners, pharmaceutical companies and individual customers, providing health education, digital medical research support, integrated health service packages and access to a wide range of health insurance products.

This transaction follows Harneys’ role as Cayman Islands counsel on the Hong Kong IPO of Quantgroup Holding Limited, which closed in late November 2025, marking two Hong Kong IPOs completed by Harneys within the last month. The Harneys team for the QingSong Health IPO and the Quantgroup IPO were led by Hong Kong Corporate Partner Raymond Ng.

Harneys’ Corporate team advises on complex cross-border transactions involving British Virgin Islands, Cayman Islands, Luxembourg and Cyprus vehicles, with a strong track record on Hong Kong listings, including healthcare and technology issuers.

For further information, please get in touch with the Harneys team at Byfield Consultancy.

Harneys advises QingSong Health Corporation on its Hong Kong IPO

Authors